Validating Mechanisms with Functional Assays

Comparative Fc profiling reveals how design choices shape effector function.

Functional assays comparing Rituximab, Ofatumumab, and Obinutuzumab show distinct complement activity profiles, despite targeting the same antigen. These differences in C1q binding, ADCD, and CDC reflect how antibody structure, including Fc engineering, impacts mechanism of action. This comparative approach supports assay development and validation aligned with therapeutic goals.

• Differentiates complement activity across similar CD20-targeting antibodies
• Confirms Ofatumumab’s enhanced CDC via strong C1q and ADCD responses
• Reveals how Fc modifications (e.g., afucosylation) alter functional outcomes